Cargando…
Impaired response to first SARS‐CoV‐2 dose vaccination in myeloproliferative neoplasm patients receiving ruxolitinib
| Autores principales: | , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley & Sons, Inc.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8420430/ https://www.ncbi.nlm.nih.gov/pubmed/34331712 http://dx.doi.org/10.1002/ajh.26305 |
| _version_ | 1783748912854597632 |
|---|---|
| author | Guglielmelli, Paola Mazzoni, Alessio Maggi, Laura Kiros, Seble Tekle Zammarchi, Lorenzo Pilerci, Sofia Rocca, Arianna Spinicci, Michele Borella, Miriam Bartoloni, Alessandro Rossolini, Gian Maria Annunziato, Francesco Vannucchi, Alessandro M. |
| author_facet | Guglielmelli, Paola Mazzoni, Alessio Maggi, Laura Kiros, Seble Tekle Zammarchi, Lorenzo Pilerci, Sofia Rocca, Arianna Spinicci, Michele Borella, Miriam Bartoloni, Alessandro Rossolini, Gian Maria Annunziato, Francesco Vannucchi, Alessandro M. |
| author_sort | Guglielmelli, Paola |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8420430 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | John Wiley & Sons, Inc. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-84204302021-09-07 Impaired response to first SARS‐CoV‐2 dose vaccination in myeloproliferative neoplasm patients receiving ruxolitinib Guglielmelli, Paola Mazzoni, Alessio Maggi, Laura Kiros, Seble Tekle Zammarchi, Lorenzo Pilerci, Sofia Rocca, Arianna Spinicci, Michele Borella, Miriam Bartoloni, Alessandro Rossolini, Gian Maria Annunziato, Francesco Vannucchi, Alessandro M. Am J Hematol Correspondences John Wiley & Sons, Inc. 2021-08-12 2021-11 /pmc/articles/PMC8420430/ /pubmed/34331712 http://dx.doi.org/10.1002/ajh.26305 Text en © 2021 The Authors. American Journal of Hematology published by Wiley Periodicals LLC. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
| spellingShingle | Correspondences Guglielmelli, Paola Mazzoni, Alessio Maggi, Laura Kiros, Seble Tekle Zammarchi, Lorenzo Pilerci, Sofia Rocca, Arianna Spinicci, Michele Borella, Miriam Bartoloni, Alessandro Rossolini, Gian Maria Annunziato, Francesco Vannucchi, Alessandro M. Impaired response to first SARS‐CoV‐2 dose vaccination in myeloproliferative neoplasm patients receiving ruxolitinib |
| title | Impaired response to first SARS‐CoV‐2 dose vaccination in myeloproliferative neoplasm patients receiving ruxolitinib |
| title_full | Impaired response to first SARS‐CoV‐2 dose vaccination in myeloproliferative neoplasm patients receiving ruxolitinib |
| title_fullStr | Impaired response to first SARS‐CoV‐2 dose vaccination in myeloproliferative neoplasm patients receiving ruxolitinib |
| title_full_unstemmed | Impaired response to first SARS‐CoV‐2 dose vaccination in myeloproliferative neoplasm patients receiving ruxolitinib |
| title_short | Impaired response to first SARS‐CoV‐2 dose vaccination in myeloproliferative neoplasm patients receiving ruxolitinib |
| title_sort | impaired response to first sars‐cov‐2 dose vaccination in myeloproliferative neoplasm patients receiving ruxolitinib |
| topic | Correspondences |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8420430/ https://www.ncbi.nlm.nih.gov/pubmed/34331712 http://dx.doi.org/10.1002/ajh.26305 |
| work_keys_str_mv | AT guglielmellipaola impairedresponsetofirstsarscov2dosevaccinationinmyeloproliferativeneoplasmpatientsreceivingruxolitinib AT mazzonialessio impairedresponsetofirstsarscov2dosevaccinationinmyeloproliferativeneoplasmpatientsreceivingruxolitinib AT maggilaura impairedresponsetofirstsarscov2dosevaccinationinmyeloproliferativeneoplasmpatientsreceivingruxolitinib AT kirossebletekle impairedresponsetofirstsarscov2dosevaccinationinmyeloproliferativeneoplasmpatientsreceivingruxolitinib AT zammarchilorenzo impairedresponsetofirstsarscov2dosevaccinationinmyeloproliferativeneoplasmpatientsreceivingruxolitinib AT pilercisofia impairedresponsetofirstsarscov2dosevaccinationinmyeloproliferativeneoplasmpatientsreceivingruxolitinib AT roccaarianna impairedresponsetofirstsarscov2dosevaccinationinmyeloproliferativeneoplasmpatientsreceivingruxolitinib AT spiniccimichele impairedresponsetofirstsarscov2dosevaccinationinmyeloproliferativeneoplasmpatientsreceivingruxolitinib AT borellamiriam impairedresponsetofirstsarscov2dosevaccinationinmyeloproliferativeneoplasmpatientsreceivingruxolitinib AT bartolonialessandro impairedresponsetofirstsarscov2dosevaccinationinmyeloproliferativeneoplasmpatientsreceivingruxolitinib AT rossolinigianmaria impairedresponsetofirstsarscov2dosevaccinationinmyeloproliferativeneoplasmpatientsreceivingruxolitinib AT annunziatofrancesco impairedresponsetofirstsarscov2dosevaccinationinmyeloproliferativeneoplasmpatientsreceivingruxolitinib AT vannucchialessandrom impairedresponsetofirstsarscov2dosevaccinationinmyeloproliferativeneoplasmpatientsreceivingruxolitinib |